{"id":603098,"date":"2024-06-01T08:07:39","date_gmt":"2024-06-01T12:07:39","guid":{"rendered":"https:\/\/platohealth.ai\/clinical-trials-show-promise-in-treating-central-nervous-system-lymphoma\/"},"modified":"2024-06-01T09:02:33","modified_gmt":"2024-06-01T13:02:33","slug":"clinical-trials-show-promise-in-treating-central-nervous-system-lymphoma","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/clinical-trials-show-promise-in-treating-central-nervous-system-lymphoma\/","title":{"rendered":"Clinical trials show promise in treating central nervous system lymphoma,","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

Boston \u2013 Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. The studies support future research in these potential breakthroughs where treatment options may be limited. The research teams will present their findings at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2024. ASCO is the world\u2019s largest clinical cancer research meeting, attracting more than 30,000 global oncology professionals.<\/p>\n

\n

Boston \u2013 Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. The studies support future research in these potential breakthroughs where treatment options may be limited. The research teams will present their findings at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2024. ASCO is the world\u2019s largest clinical cancer research meeting, attracting more than 30,000 global oncology professionals.<\/p>\n

These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.<\/p>\n

A full list of Dana-Farber Oral Presentations at the 2024 ASCO Annual Meeting is available here.<\/p>\n

A full list of Dana-Farber Poster Discussions at the 2024 ASCO Annual Meeting is available here.<\/p>\n

CAR T-cell therapy shows promise in patients with central nervous system lymphoma<\/strong> <\/p>\n

A CAR T-cell therapy approved for patients with large B cell lymphoma has produced positive results in a pilot study involving patients with relapsed, treatment-resistant central nervous system (CNS) lymphoma, Dana-Farber investigators report. The therapy, axicabtagene ciloleucel, was found to be safe and well tolerated in the 18 study participants and had an overall response rate of 94%. The median progression-free survival \u2013 the time in which patients lived without the cancer worsening \u2013 was 14.3 months, and the median overall survival was 26.4 months. The most common side effects, cytokine release syndrome and immune effector cell-associated neurologic syndrome (ICANS) that are inflammatory conditions often associated with CAR T-cell therapy, were manageable. CNS lymphoma is a rare non-Hodgkin lymphoma in which malignant cells form in the lymph tissue of the brain or spinal cord. Although initial treatment is often effective, better treatments are needed when the disease recurs. CAR T-cell therapies use genetically modified versions of a patient\u2019s own immune system T cells to attack cancer cells in the body. <\/p>\n